Publications by authors named "V Odone Filho"
SARS-CoV-2 Genomic Variants and Their Relationship with the Expressional and Genomic Profile of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2).
Microorganisms
November 2024
Over the past four years, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) have been extensively studied, given their important role in SARS-CoV-2 replication; however, most studies have failed to compare their behavior in the face of different SARS-CoV-2 genomic variants. Therefore, this study evaluated the influence of different variants in ACE2/TMPRSS2 expressional and genomic profiles. To achieve this, 160 nasopharyngeal samples, previously detected with SARS-CoV-2 via RT-qPCR (June 2020-July 2022), were quantified for ACE2/TMPRSS2 expression levels, also using RT-qPCR; SARS-CoV-2 genomic variants, along with polymorphisms in the ACE2/TMPRSS2 coding genes, were identified using nanopore sequencing.
View Article and Find Full Text PDFPurpose: The purpose of this study is to analyze the associations between participation in physical education (PE) classes and days with ≥60 minutes of moderate- to vigorous-intensity physical activity (MVPA) using different reference categories for participation in PE.
Methods: We used self-reported data from 284,820 adolescents.
Results: When no participation in PE was the reference, participation on 1 (prevalence ratio [PR] = 1.
Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.
Semin Arthritis Rheum
December 2024
Article Synopsis
- The study compared the risks of major adverse cardiovascular events (MACE) and all-cause death (ACD) in rheumatoid arthritis patients treated with JAK inhibitors (JAKi) or tocilizumab (TCZ) versus tumor necrosis factor inhibitors (TNFi).
- A systematic review of randomized controlled trials showed that JAKi were associated with a non-significant increase in risks for MACE and ACD compared to TNFi, with Bayesian analysis indicating a higher probability of these events occurring with JAKi.
- The analysis highlighted the need for more data, particularly on JAKi other than tofacitinib, to make informed regulatory recommendations regarding their use.
Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
J Gastroenterol Hepatol
September 2024
Article Synopsis
- Type 2 diabetes (T2DM) is often linked with liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), and there is interest in whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) can help prevent serious liver problems.
- A study analyzed data from nine cohort studies involving over half a million T2DM patients and found that using GLP-1RAs lowered the risk of liver cancer and severe liver complications, with no significant biases in the data.
- The findings highlight that GLP-1RAs could be more effective for liver protection compared to other diabetes medications, but more long-term studies are needed for confirmation.
Background: Neuroblastomas account for 8-10 % of all cancer diagnoses among children. Most patients present with advanced, high-risk disease and 90 % are less than five years old. The burden of morbidity and mortality is high and is quantifiable by measures of health-related quality of life (HRQL).
View Article and Find Full Text PDF